

# Mosaic Disorders in Children

**Nicole Knöpfel**

Great Ormond Street Hospital for Children and

Mosaicism and Precision Medicine Laboratory,  
Francis Crick Institute, London UK





# Overview

- **What is a mosaic?**

Definition and types of mosaicism

- **Cutaneous mosaicism in children**

- **Approach to a suspected mosaic patient**



What is a mosaic?

---



# Mosaicism - traditional definition

- The coexistence of cells with at least two genotypes, in an individual derived from a single zygote

## Problems

- We all have mutations *in utero* all the time
- We all have mutations after birth all the time – naevi, cancer etc.



We are all mosaic by this definition



# Mosaicism – definition updated from genetic knowledge

## Mosaic disorder

The coexistence of cells with at least two genotypes, **by the time of birth\***, in an individual derived from a single zygote, where the postzygotic mutation has led to **the whole disease phenotype**.

\* This does not mean that the phenotype has to be present at birth



# Classification of mosaicism according to..

## **Mechanism of origin**

- Single-point mutation, loss of heterozygosity, recombination, non-disjunction

## **Organ involvement**

- Somatic, gonadal, gonado-somatic

## **Pattern**

- Segmental (with a pattern), non-segmental

## **Category**

- Genomic or epigenetic

## **Timing**

- Very early, early, late or postnatal

## **Direction**

- Forward or backwards




Classification of mosaicism according to..

# Organ involvement




Only somatic cells



Somatic  
Mosaicism

Not passed on


Only gonadal cells (germinal)



Gonadal  
Mosaicism

Passed on

Somatic and gonadal cells



Gonado-somatic  
Mosaicism

Passed on


Classification of mosaicism according to..

# Patterns



# The Categories of Cutaneous Mosaicism: A Proposed Classification Rudolf Happle\*

## 1. Non-segmental Mosaicism



Single point mosaicism




Disseminated mosaicism




Patchy mosaicism without midline separation

## 2. Segmental Mosaicism



Lines of Blaschko




Block or flag-like pattern



Phylloid pattern



Lateralization pattern









Round / oval



Triangular



## ***Actb* mosaicism**




Becker's naevus

## ***Gnaq/11* mosaicism**




Classification of mosaicism according to..


Category







Lethal, dominant diseases



## Genomic mosaicism of dominant lethal mutations




Normal  
individual



Segmental  
mosaicism

Naevus



Segmental  
mosaicism

Syndrome



# The exact same mutation *GNAQ* p.R183Q

Isolated port wine stain




Sturge-Weber syndrome

# GNAQ/GNA11 Mosaicism

## Mosaic Activating Mutations in *GNA11* and *GNAQ* Are Associated with Phakomatosis Pigmentovascularis and Extensive Dermal Melanocytosis

Anna C. Thomas<sup>1,18</sup>, Zhiqiang Zeng<sup>2,18</sup>, Jean-Baptiste Rivière<sup>3,18</sup>, Ryan O'Shaughnessy<sup>4</sup>, Lara Al-Olabi<sup>1</sup>, Judith St-Onge<sup>3</sup>, David J. Atherton<sup>5</sup>, H  l  ne Aubert<sup>5</sup>, Lorea Bagazgoitia<sup>7</sup>, S  bastien Barbarot<sup>6</sup>, Emmanuelle Bourrat<sup>8,9</sup>, Christine Chiaverini<sup>10</sup>, W. Kling Chong<sup>11</sup>, Yannis Duffourd<sup>3</sup>, Mary Glover<sup>5</sup>, Leopold Groesser<sup>12</sup>, Smail Hadj-Rabia<sup>13</sup>, Henning Hamm<sup>14</sup>, Rudolf Happle<sup>15</sup>, Imran Mushtaq<sup>16</sup>, Jean-Philippe Lacour<sup>10</sup>, Regula Waelchli<sup>5</sup>, Marion Wobser<sup>14</sup>, Pierre Vabres<sup>3,17,19</sup>, E. Elizabeth Patton<sup>2,19</sup> and Veronica A. Kinsler<sup>1,5,19</sup>




*A single somatic mutation in GNA11 or GNAQ is responsible for both types of cutaneous lesion in PPV*

# Mosaicism of activating *FGFR3* mutations in human skin causes epidermal nevi

Christian Hafner,<sup>1</sup> Johanna M.M. van Oers,<sup>2</sup> Thomas Vogt,<sup>1</sup> Michael Landthaler,<sup>1</sup> Robert Stoehr,<sup>1</sup> Hagen Blaszyk,<sup>4</sup> Ferdinand Hofstaedter,<sup>5</sup> Ellen C. Zwarthoff,<sup>2</sup> and Arndt Hartmann<sup>5</sup>

<sup>1</sup>Department of Dermatology, University of Regensburg, Regensburg, Germany; <sup>2</sup>Department of Pathology, Josephine Nefkens Institute, Erasmus MC, Rotterdam, The Netherlands; <sup>3</sup>Department of Urology, University of Regensburg, Regensburg, Germany; <sup>4</sup>Department of Pathology, University of Vermont College of Medicine, Burlington, Vermont, USA; <sup>5</sup>Institute of Pathology, University of Regensburg, Regensburg, Germany.




**Figure 3**  
Patient 32 had a common soft-type epidermal nevus on his back. Two biopsies were taken from the epidermal nevus and the adjacent normal skin. The epidermal nevus histologically showed the typical acanthosis and papillomatosis (H&E staining; original magnification,  $\times 40$ ) and an R248C mutation in the SNaPshot analysis. In contrast, the clinically and histologically normal epidermis revealed a WT status for codon 248. This result suggests a strong genotype-phenotype correlation and the presence of a mosaicism of the *FGFR3* mutation in the epidermis of this patient.

Somatic mosaicism

SHORT REPORT

## Keratinocytic epidermal nevi are associated with mosaic *RAS* mutations

Christian Hafner,<sup>1</sup> Agusti Toll,<sup>2</sup> Susanne Gantner,<sup>1</sup> Andreas Mauerer,<sup>1</sup> Irene Lurkin,<sup>3</sup> Francesco Acquadro,<sup>4</sup> Alejandro Fernández-Casado,<sup>2</sup> Ellen C Zwarthoff,<sup>3</sup> Wolfgang Dietmaier,<sup>5</sup> Eulalia Baselga,<sup>6</sup> Elisabet Parera,<sup>2</sup> Asunción Vicente,<sup>7</sup> Ariel Casanova,<sup>8</sup> Juan Cigudosa,<sup>4</sup> Thomas Mentzel,<sup>9</sup> Ramon M Pujol,<sup>2</sup> Michael Landthaler,<sup>1</sup> Francisco X Real<sup>8,10</sup>



9591||

## Somatic embryonic *FGFR2* mutations in keratinocytic epidermal nevi


Agustí Toll<sup>1,\*</sup>, Luis C. Fernández<sup>2,\*</sup>, Tirso Pons<sup>3</sup>, Leopold Groesser<sup>4</sup>, Ana Sagrera<sup>2</sup>, Enrique Carrillo-de Santa Pau<sup>2</sup>, Asunción Vicente<sup>5</sup>, Eulàlia Baselga<sup>6</sup>, Miguel Vázquez<sup>3</sup>, Sergi Beltrán<sup>7</sup>, David G. Pisano<sup>8</sup>, Daniel Rueda<sup>9</sup>, Marta Gut<sup>7</sup>, Ramon M. Pujol<sup>1</sup>, Christian Hafner<sup>1</sup>, Ivo Gut<sup>7</sup>, Alfonso Valencia<sup>3</sup>, Francisco X. Real<sup>1, 10</sup>

\* Show more


## Oncogenic *PIK3CA* mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern

Christian Hafner<sup>\*</sup>, Elena López-Knowles<sup>†</sup>, Nuno M. Luis<sup>†</sup>, Agustí Toll<sup>†</sup>, Eulàlia Baselga<sup>§</sup>, Alex Fernández-Casado<sup>†</sup>, Silvia Hernández<sup>†</sup>, Adriana Ribé<sup>†</sup>, Thomas Mentzel<sup>\*\*</sup>, Robert Stoehr<sup>††</sup>, Ferdinand Hofstaedter<sup>††</sup>, Michael Landthaler<sup>†</sup>, Thomas Vogt<sup>†</sup>, Ramon M. Pujol<sup>†</sup>, Arndt Hartmann<sup>†††§</sup>, and Francisco X. Real<sup>††§§</sup>

Departments of <sup>\*</sup>Dermatology and <sup>†</sup>Urology and <sup>††</sup>Institute of Pathology, University of Regensburg, 93042 Regensburg, Germany; <sup>†††</sup>Unitat de Biologia Cel·lular i Molecular, Institut Municipal d'Investigació Mèdica, Carrer del Dr. Aiguader 88, 08003 Barcelona, Spain; <sup>††††</sup>Servei de Dermatologia, Hospital del Mar, Universitat Autònoma de Barcelona, Passeig Marítim 25, 08003 Barcelona, Spain; <sup>†††††</sup>Servei d'Anatomia Patològica and <sup>††††††</sup>Servei de Dermatologia, Hospital de Sant Pau, Universitat Autònoma de Barcelona, 08025 Barcelona, Spain; <sup>†††††††</sup>Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Carrer del Dr. Aiguader 88, 08003 Barcelona, Spain; <sup>††††††††</sup>Department of Dermatopathology, 88048 Friedrichshafen, Germany; and <sup>†††††††††</sup>Department of Pathology, University of Erlangen-Nürnberg, 91054 Erlangen, Germany



**Fig. 1.** Morphological similarities of linear lesions of congenital EN from a child following Blaschko's lines (A) and SK from an elderly patient (B). At the microscopic level, both lesions are characterized by acanthosis, papillomatosis, and variable degrees of hyperkeratosis and hyperpigmentation (C, EN; D, SK).



**Fig. 2.** Mutational analysis of EN and SK. In all cases, the mutant sequence was accompanied by the presence of the WT allele, indicating heterozygosity.




# Mutational spectrum in FGFR3



Germinal



Early embryo



Late embryo



Adult life




Adult life




Development Anomaly



Tanatophoric dysplasia



Epidermal Naevus syndrome




Naevus

Common epidermal naevus



Tumour

Seborrheic queratosis










Cancer

Bladder cancer

# Cerebriform sebaceous nevus: a subtype of organoid nevus due to specific postzygotic FGFR2 mutations

JEADV 2021


M. Theiler,<sup>1,\*</sup>  L. Weibel,<sup>1</sup>  S. Christen-Zaech,<sup>2</sup>  V. Carnignac,<sup>3</sup>  A. Sorlin,<sup>3,4</sup> K. Neuhaus,<sup>5</sup>   
 M. Chevarin,<sup>3</sup> C. Thauvin-Robinet,<sup>3,4,6</sup> C. Philippe,<sup>3,6</sup> L. Faivre,<sup>3,4,6</sup> P. Vabres,<sup>3,6,7,†</sup> P. Kuentz<sup>3,6,8,†</sup> 



# Three novel pathogenic *NEK9* variants in patients with nevus comedonicus: A case series


JAAD 2021

Hazem A. Juratli MD<sup>a</sup>, Sabine Jäggle PhD<sup>b</sup>, Martin Theiler MD<sup>c</sup>, Dario Didona MD<sup>a</sup>, Rudolf Happle MD<sup>d</sup>, Nicole Knöpfel MD<sup>c</sup>, Lisa Weibel MD<sup>c</sup>, Judith Fischer MD, PhD<sup>b</sup> ✉



Patient	Nucleotide change <sup>a</sup>	Protein change	Variant type	Exon	Coverage	Reads alternative allele	Mosaic percentage	Associated figure
P1	c.1756_1758del	p.(Thr586del)	In frame deletion	15	1090–1105x	74-75	6.6%	Supplemental Figure 2, A
P2	c.1738_1752del	p.(His580_Tyr584del)	In frame deletion	15	1042–1302x	69-70	5.9%	Supplemental Figure 2, B
P3	c.373_375delinsATT	p.(Leu125Ile)	Indel/missense	2	1136–1144x	87	7.6%	Supplemental Figure 2, C
P4	c.1718T>G	p.(Ile573Ser)	Missense	14	1272x	212	16.7%	Supplemental Figure 2, D


<sup>a</sup>*NEK9* reference sequence NM\_033116.5 (GRCh37.p13).





## Genomic mosaicism of dominant lethal mutations


- Sturge-Weber syndrome (GNAQ/GNA11)
- Epidermal naevus and epidermal naevus syndrome (FGFR3, FGFR2, HRAS, PIK3CA)
- Sebaceous naevus and sebaceous naevus syndrome (KRAS, HRAS, FGFR2)
- PROS spectrum (PIK3CA)
- Proteus syndrome (AKT1)
- Spilus naevus and related (HRAS, PTPN11)
- McCune-Albright syndrome (GNAS)
- Maffucci syndrome (IDH1, IDH2)
- Congenital melanocytic naevus and CMN syndrome (NRAS)
- Becker naevus and Becker naevus syndrome (ACTB)
- Naevus comedonicus and naevus comedonicus syndrome (NEK9)
- Encephalocraneocutaneous syndrome (FGFR1)
- Vabres syndrome (RhoA)




## Genomic mosaicism of non-lethal, dominant mutations




Normal individual



Affected individual



Mosaicism type 1




Mosaicism type 2

Simple segmental mosaicism of dominant non-lethal diseases

Superimposed segmental mosaicism of dominant non-lethal diseases





## Simple segmental mosaicism of dominant, non-lethal diseases (confirmed by genetic analysis)

- Neurofibromatosis 1 (NF1)
- Gorlin syndrome (PTCH1, PTCH2, SUFU)
- Glomangiomas, GVM (GLML)
- Familial leiomyomatosis with kidney cancer (FH)
- Tuberous sclerosis complex (TSC1, TSC2)
- Epidermolytic ichthyosis Brocq (KRT1, KRT10)
- Superficial epidermolytic ichthyosis Siemens (K2)
- Darier disease (ATP2A2)
- Hailey-Hailey disease (ATP2C1)
- Pachyonychia congenita (KRT16)
- Dowling-Degos disease, Galli-Galli variant (KRT5)
- Keratitis-ichthyosis-deafness syndrome, KID (GJB24)

# Mutations in K1 or K10

Germinal

During embryo development

Epidermolytic ichthyosis

Epidermolytic epidermal naevus




# Mutations in connexin 26 (GJB2)



Germinal

During embryo development

Keratitis-ichthyosis-deafness  
(KID) syndrome

Porokeratotic eccrine ostial and dermal duct nevus  
(PEODDN)






## Superimposed mosaicism in AD non-lethal diseases (confirmed by genetic analysis)

- Darier disease
- Gorlin syndrome
- Hailey-Hailey disease
- Osteomatosis cutis hereditaria
- Legius syndrome
- Neurofibromatosis 1
- Disseminated superficial actinic porokeratosis
- PTEN hamartoma syndrome
- CM-AVM syndrome





# PTCH1



Classification of mosaicism according to..

# Category





## Mosaicism of X-linked genes

### Dominant: Females affected, lethal in males

- Incontinentia pigmenti (NEMO)
- Focal dermal hypoplasia (PORCN)
- Conradi-Hünemann-Happle syndrome (EBP)
- CHILD syndrome (NSDHL)
- MIDAS syndrome / MLS (COX7B)
- Oro-facio-digital syndrome (CXORF5)

### Recessive: Males affected, females carriers (healthy or mosaic)

- Hypohidrotic ectodermal dysplasia, X-linked (EDA)
- Dikeratosis congenita, X-linked (DKC1)
- Menkes syndrome (ATP7A9)
- IFAP syndrome: Follicular ichthyosis, atrichia and photophobia (MBTPS2)
- Reticulated pigmented anomaly of Partington (POLA1)
- Borjesson-Forssman-Lehman syndrome (PHF6)




# CHILD


- Congenital *hemidysplasia* with *ichthyosiform* nevus and *limb defects*
- Mutations in *NSDHL* (NAD steroid deshydrogenase)
- X-linked dominant

Table 1. Summary of Mutations Described in CHILD Syndrome

Serial No.	Source	No. of Cases	Mutation	Exon
1	Konig et al <sup>8</sup>	1	R88X	3
2	Konig et al <sup>8</sup>	3	A105V	4
3	Konig et al <sup>8</sup>	1	G205S	6
4	Konig et al <sup>8</sup>	1	Q210X	6
5	Konig et al <sup>9</sup>	1	A182P	6
6	Hummel et al <sup>10</sup>	1	E151X	5
7	Murata et al <sup>11</sup>	1	Y349C	8



Konig A, Happle R



# Targeting epidermal lipids for treatment of Mendelian disorders of cornification

Dimitra Kiritsi<sup>1</sup>, Franziska Schauer<sup>1</sup>, Ute Wölfle<sup>1</sup>, Manthoula Valari<sup>2</sup>, Leena Bruckner-Tuderman<sup>1</sup>, Cristina Has<sup>1\*</sup> and Rudolf Happle<sup>1</sup>

## Abstract

**Background:** Inherited ichthyoses or Mendelian disorders of cornification (MeDOC) are clinically heterogeneous disorders with high unmet therapeutic needs, which are characterized by skin hyperkeratosis and scaling. Some MeDOC types are associated with defects of the epidermal lipid metabolism, resulting in perturbed barrier permeability and subsequent epidermal hyperplasia, hyperkeratosis and inflammation. An example is the CHILD (congenital hemidysplasia with ichthyosiform nevus and limb defects) syndrome, an X-linked dominant multisystem MeDOC caused by mutations in the *NSDHL* (NAD(P)H steroid dehydrogenase-like protein) gene, which is involved in the distal cholesterol biosynthetic pathway. The skin manifestations of the CHILD syndrome have been attributed to two major mechanisms: deficiency of cholesterol, probably influencing the proper corneocyte membrane formation, and toxic accumulation of aberrant steroid precursors.

**Methods:** Here we addressed the efficacy of an ointment containing cholesterol and simvastatin, an agent inhibiting endogenous cholesterol synthesis, in the treatment of patients with CHILD syndrome. To test the specificity of the therapy, we treated patients with CHILD syndrome and patients with other types of MeDOC.

**Results:** The therapy with simvastatin and cholesterol was effective in CHILD syndrome patients; only lesions in the CHILD syndrome patients improved, while patients with other types of MeDOC did not improve.

**Conclusions:** This therapy with simvastatin and cholesterol is effective in CHILD syndrome patients because both simvastatin and cholesterol are available worldwide. Our data provide initial evidence of the specificity of the therapeutic effect of the simvastatin-cholesterol ointment in CHILD syndrome in comparison to other types of MeDOC.

**Keywords:** Cholesterol, Mosaicism, Ichthyosis, Simvastatin, CHILD nevus, *NSDHL* mutations


Simvastatin 2 %  
Cholesterol 2 %

Classification of mosaicism according to..

## Direction

- Forwards or backwards





Forwards

→ pathogenic mutation



Revertant mosaicism

Reverse



pathogenic → Normal genotype



Revertant mosaicism or 'natural gene therapy', a phenomenon in which germline mutations are corrected by somatic events

# Mitotic Recombination in Patients with Ichthyosis Causes Reversion of Dominant Mutations in *KRT10*

Keith A. Choate<sup>1,2</sup>, Yin Lu<sup>2</sup>, Jing Zhou<sup>1</sup>, Murim Choi<sup>2</sup>, Peter M. Elias<sup>3</sup>, Anita Farhi<sup>2</sup>, Carol Nelson-Williams<sup>2</sup>, Debra Crumrine<sup>3</sup>, Mary L. Williams<sup>3</sup>, Amy J. Nopper<sup>4</sup>, Alanna Bree<sup>5</sup>, Leonard M. Milstone<sup>1</sup>, and Richard P. Lifton<sup>2,‡</sup>






# Our approach to mosaic disorders

# Our approach to mosaic disorders

## 1 – Identify a mosaic disorder




PATTERNS

## 2 – Full history and systems exam; Family history

## 3 – Investigations: histology and genetics



## The general approach to the suspected mosaic patient



# Mosaic abnormalities of the skin: review and guidelines from the European Reference Network for rare skin diseases\*

V.A. Kinsler<sup>1,2</sup>, O. Boccardi<sup>3</sup>, S. Fraïtag<sup>4</sup>, A. Torrelo<sup>5</sup>, P. Vabres<sup>6,7</sup> and A. Diociaiuti<sup>8</sup>

<sup>1</sup>Pediatric Dermatology, Great Ormond Street Hospital for Children, London, U.K.

<sup>2</sup>Genetics and Genomic Medicine, UCL Institute of Child Health, London, U.K.

<sup>3</sup>Department of Dermatology and Reference Centre for Genodermatoses and Rare Skin Diseases (MAGEC), Université Paris Descares – Sorbonne Paris Cité, Institut Imagine, Paris, France

<sup>4</sup>Department of Pathology, Hôpital Universitaire Necker-Enfants Malades, APHP, Paris, France

<sup>5</sup>Department of Dermatology, Hospital Infantil del Niño Jesús, Madrid, Spain

<sup>6</sup>Department of Dermatology and Reference Centre for Rare Skin Diseases, Dijon University Hospital, Dijon, France

<sup>7</sup>GAD, Genetics of Anomalies of Development, University of Bourgogne, Dijon, France

<sup>8</sup>Dermatology Unit, Bambino Gesù Children's Hospital, Rome, Italy

## Summary

### Correspondence

V.A. Kinsler

E-mail: v.kinsler@ucl.ac.uk

### Accepted for publication

19 March 2019

### Funding sources

None.

### Conflicts of interest

None declared.

\*Plain language summary available online

DOI 10.1111/bjd.17924

**Background** Cutaneous mosaicism is an area of dermatology in which there has been an explosion of knowledge within the current decade. This has led to fundamental changes in the understanding of the conditions in this field, and to an ongoing paradigm shift in the approach to management of mosaic skin disorders.

**Objectives** To lay out the general principles of mosaicism as they are currently understood, summarize the known cutaneous mosaic abnormalities of the skin with associated phenotypic and genotypic information, review the latest trials on targeted therapies and propose guidelines for the general approach to a patient with suspected mosaicism.

**Methods** This was a consensus expert review as part of the European Reference Network project (ERN-Skin).

**Conclusions** This study provides clinicians with a practical approach to the patient with suspected mosaicism, redefines mosaicism for the modern genetic era, and proposes a new classification system based on genetic mechanism.

### What's already known about this topic?

- Cutaneous mosaicism is a complex field of dermatology that encompasses most birthmarks, and many rare syndromes.
- Some cutaneous patterns are known to be seen in mosaicism.
- Very few treatment options are available for most mosaic abnormalities of the skin.
- Recent high-sensitivity genetic techniques have led to an explosion of knowledge about genotype and phenotype in the literature.

### What does this study add?

- Expert consensus from the European Reference Network project.
- Review of knowledge of confirmed mosaic abnormalities of the skin, including cutaneous phenotype, extracutaneous associated features and genotype.
- Proposed new classification of mosaic abnormalities of the skin by genetic mechanism and therefore inheritance potential.
- Practical tips on correct sample collection and genetic investigation.
- Review of trials of targeted therapies.
- Guidelines for a practical clinical approach to the patient with suspected mosaicism.

# If you want to explore more on mosaicism

